BR112017024283A8 - Vacinas contra a dengue - Google Patents

Vacinas contra a dengue

Info

Publication number
BR112017024283A8
BR112017024283A8 BR112017024283A BR112017024283A BR112017024283A8 BR 112017024283 A8 BR112017024283 A8 BR 112017024283A8 BR 112017024283 A BR112017024283 A BR 112017024283A BR 112017024283 A BR112017024283 A BR 112017024283A BR 112017024283 A8 BR112017024283 A8 BR 112017024283A8
Authority
BR
Brazil
Prior art keywords
denv
conserved
vaccines against
dengue
against dengue
Prior art date
Application number
BR112017024283A
Other languages
English (en)
Other versions
BR112017024283A2 (pt
Inventor
Reyes-Sandoval Arturo
Lopez-Camacho Cesar
Blight Joshua
Original Assignee
Univ Oxford Innovation Ltd
Blight Joshua
Baseimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oxford Innovation Ltd, Blight Joshua, Baseimmune Ltd filed Critical Univ Oxford Innovation Ltd
Publication of BR112017024283A2 publication Critical patent/BR112017024283A2/pt
Publication of BR112017024283A8 publication Critical patent/BR112017024283A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

VACINAS CONTRA A DENGUE. A presente invenção se refere a uma proteína que compreende uma pluralidade de sequências de peptídeos conservadas, ou variantes das mesmas, em que pelo menos uma das sequências conservadas é conservada através de todos os quatro sorotipos do vírus da dengue DENV-1, DENV-2, DENV-3 e DENV-4, e em que as sequências conservadas compreendem pelo menos parte de uma sequência de uma ou mais proteínas não estruturais dos sorotipos do vírus da dengue. A invenção se refere adicionalmente a peptídeos, composições, ácidos nucleicos, vetores virais, partículas semelhantes a vírus, uso, kits de vacinação de iniciação e reforço, agentes e métodos associados.
BR112017024283A 2015-05-12 2016-05-11 Vacinas contra a dengue BR112017024283A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1508099.7A GB201508099D0 (en) 2015-05-12 2015-05-12 Dengue vaccines
PCT/GB2016/051358 WO2016181147A1 (en) 2015-05-12 2016-05-11 Dengue vaccines

Publications (2)

Publication Number Publication Date
BR112017024283A2 BR112017024283A2 (pt) 2018-07-24
BR112017024283A8 true BR112017024283A8 (pt) 2022-12-27

Family

ID=53489497

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017024283A BR112017024283A8 (pt) 2015-05-12 2016-05-11 Vacinas contra a dengue

Country Status (6)

Country Link
US (1) US10350285B2 (pt)
EP (1) EP3294331A1 (pt)
BR (1) BR112017024283A8 (pt)
GB (1) GB201508099D0 (pt)
MX (1) MX2017014417A (pt)
WO (1) WO2016181147A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11806393B2 (en) * 2017-02-10 2023-11-07 La Jolla Institute For Allergy And Immunology Flavivirus peptide sequences, epitopes, and methods and uses thereof
BR112020009157A2 (pt) * 2017-11-09 2020-10-27 Institut Pasteur poliepítopo quimérico, polinucleotídeo, vetor, célula hospedeira e composição imunogênica
WO2022169665A1 (en) * 2021-02-05 2022-08-11 Unm Rainforest Innovations Bacteriophage virus-like particle vaccines against flavivirus non-structural protein 1

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002356690B2 (en) * 2001-12-04 2008-07-24 Bavarian Nordic A/S Flavivirus NS1 subunit vaccine
WO2011163628A2 (en) 2010-06-24 2011-12-29 La Jolla Institute For Allergy And Immunology Dengue virus (dv) polypeptide sequences, t cell epitopes and methods and uses thereof

Also Published As

Publication number Publication date
BR112017024283A2 (pt) 2018-07-24
US10350285B2 (en) 2019-07-16
GB201508099D0 (en) 2015-06-24
WO2016181147A1 (en) 2016-11-17
US20180193446A1 (en) 2018-07-12
EP3294331A1 (en) 2018-03-21
MX2017014417A (es) 2018-06-20

Similar Documents

Publication Publication Date Title
BR112018011711A2 (pt) peptídeos de direcionamento para direcionar virus adeno-associados (aav)
CO2020004738A2 (es) Variantes de cápsides de virus adenoasociados y métodos de uso de estas
BR112019001532A2 (pt) proteínas de capsídeo de vírus adenoassociado inovadoras
WO2017058892A3 (en) Methods and compositions for antibody-evading virus vectors
BR112019007433A2 (pt) sistemas de replicon de vírus recombinante e usos dos mesmos
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
MX2017012097A (es) Variantes de virus adenoasociado y métodos de uso de estas.
BR112018012962A2 (pt) vacinas de zika recombinantes
CL2023000264A1 (es) Nuevos vectores virales adeno-asociados dirigidos al hígado
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
BR112018011975A2 (pt) composições úteis no tratamento de atrofia muscular espinhal
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
CO2017007105A2 (es) Nuevos virus de tilapia
AR108781A1 (es) Aumento de la inmunogenicidad del péptido l2 de virus de papiloma humano (hpv)
CA3009928A1 (en) Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine
BR112019002904A2 (pt) métodos e composições para transferência gênica direcionada
CY1124707T1 (el) Συνθεσεις και μεθοδοι για την επαγωγη ενισχυμενης ανοσοαποκρισης με χρηση φορεων ιων poxvirus (ευλογοϊων)
AR108014A1 (es) Vacuna universal para enfermedades virales y método de vacunación
BR112017024283A8 (pt) Vacinas contra a dengue
HRP20240163T1 (hr) Metode i pripravci za izazivanje zaštitnog imuniteta protiv infekcije filovirusom
EP3939604A3 (en) Influenza hemagglutinin protein vaccines
BR112018008840A8 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
AR094810A1 (es) Parvovirus porcino 5b, métodos de uso y vacuna
EA201990719A1 (ru) Новые промоторы
AR095425A1 (es) Vacuna, uso y procedimiento para prevenir una infección por picornavirus

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: JOSHUA BLIGHT (GB)

B25A Requested transfer of rights approved

Owner name: BASEIMMUNE LTD (GB)

B25G Requested change of headquarter approved

Owner name: BASEIMMUNE LTD (GB)